Pheochromocytoma D35.0

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 04.11.2026

Dieser Artikel auf Deutsch

Synonym(s)

Pheochromocytoma; Pheochromocytoma / Paraganglioma

History
This section has been translated automatically.

Felix Fränkel 1886; the Berlin pathologist Ludwig Pick was the first to use the term pheochromocytoma in 1912.

Definition
This section has been translated automatically.

Pheochromocytomas (from the Greek φαιός (phaios) = dark and χρώμα (chroma) = color) are rare, catecholamine-producing, spontaneously occurring, but also hereditary (about 25%), neuroendocrine tumors that are unilateral (about 90%) or bilateral tumors of the chromaffin tissue of the adrenal medulla (80% of pheochromocytomas are located in the adrenal medulla) or the extraadrenal paraganglia ( see below: paragangliomas) (Farrugia FA et al. 2019). In children, approximately 30% of the tumors are located extraadrenally.

Approximately 60% of pheochromocytomas secrete both epinephrine and norepinephrine. Extraadrenal pheochromocytomas (which are referred to as paragangliomas) located above the diaphragm produce only norepinephrine; malignant pheochromocytomas also produce the catecholamine dopamine.

 

Classification
This section has been translated automatically.

Spontaneous pheochromocytomas (75%)

Hereditary pheochromocytomas (25%):

Occurrence/Epidemiology
This section has been translated automatically.

Incidence: < 1/100,000/year (2–8 cases per 1 million inhabitants). The prevalence of the disease is estimated at 0.05–0.13% in the general population and at 0.1–0.5% among patients with high blood pressure. Approximately 0.1% of all cases of hypertension are caused by a pheochromocytoma.    

Etiopathogenesis
This section has been translated automatically.

About 25% of pheochromocytomas are hereditary and occur in the context of syndromes:

In a number of pheochromocytomas, germline or somatic mutations can be detected.

Manifestation
This section has been translated automatically.

Median age for sporadic forms is 40–50 years; for hereditary forms, it is < 40 years. In a large Spanish study of 693 unselected patients with pheochromocytomaand paraganglioma patients, 69% were diagnosed with a pheochromocytoma, 15% with a sympathetic paraganglioma, and 22% with a parasympathetic paraganglioma (Cascon A et al. 2009). A smaller proportion was found to be of the mixed type.

Clinic
This section has been translated automatically.

Paroxysmal hypertension with hypertensive crises (50% in adults) or persistent hypertension (50% in adults—but 90% in children). During a hypertensive crisis, which can sometimes be triggered by palpation of the abdomen, patients complain of headaches.

Headaches 70–90%, sweating (65–70%), tachycardia (50–70%), heat intolerance (40–70%), tremors (40–50%), pallor (40–45%), weight loss (35–40%), nervousness, panic, and anxiety (35–40%), angina pectoris (20–50%). Absence of nocturnal blood pressure dip during 24-hour blood pressure monitoring. Possible paradoxical rise in blood pressure following administration of beta-blockers.

Additional findings: Pale skin, hyperglycemia, and glucosuria (1/3 of cases), leukocytosis, weight loss (hypermetabolism)

Diagnostics
This section has been translated automatically.

Laboratory! (Blood plasma: Measurement of meta- and normetanephrines [catecholamine metabolites]; 24-hour urine: Measurement of meta- and normetanephrines; if necessary, measurement of catecholamines.

If an excess of hormones is confirmed, imaging studies are performed: (Endo-)ultrasound, CT, and MRI are suitable for visualizing the adrenal region (sensitivity approximately 95% and specificity approximately 75%). In cases of extraadrenal pheochromocytomas (paragangliomas), further imaging is required.

In most cases, abdominal CT or MRI, as well as scintigraphy or SPECT (Single Photon Emission Computed Tomography) with 123I-MIBG(metaiodobenzylguanidine), are used. If the MIBG/SPECT results are negative but a tumor is still suspected, somatostatin receptor scintigraphy may also be performed.

 

Histology
This section has been translated automatically.

Polygonal and spindle-shaped chromaffin cells and supporting cells arranged in cell bales. Most common are cell nuclear atypes. Mostly good vascularization of the parenchyma. A malignant pheochromocytoma is only diagnosed when metastases are detected. Metastases occur in regional lymph nodes or haematogenically preferably in the liver, lungs and bones.

Diagnosis
This section has been translated automatically.

Suspected cases include sporadic, treatment-resistant hypertension (or hypertensive crises) accompanied by palpitations, headaches, unexplained sweating, pallor, and a lack of nocturnal blood pressure decline as measured by 24-hour blood pressure monitoring (evidence of autonomic catecholamine overproduction).

 

Note:

Biochemical testing should be performed in the following patients:

  • Patients with newly onset, treatment-resistant hypertension, Patients with a paradoxical blood pressure response during anesthesia or surgical procedures, patients with a hereditary predisposition to pheochromocytoma, asymptomatic patients with an adrenal incidentaloma, and patients with sudden panic attacks.
  • Note: Discontinue interfering medications 2 weeks prior to laboratory testing if possible (e.g., sympathomimetics, α-receptor blockers, antidepressants, clonidine). Diuretics, calcium channel blockers, ACE inhibitors, and sartans may be continued.
  • Determination of free plasma metanephrines under strict sampling conditions (establishment of a venous access, at least 30 minutes of rest for the patient prior to blood collection). A pheochromocytoma is likely if individual values are more than three times the normal range or if both metanephrine and normetanephrine are elevated simultaneously. Alternatively, fractionated metanephrines can be measured in acidified 24-hour urine. Additionally, measure 3-methoxytyramine, dopamine, and homovanillic acid in plasma.
  • Clonidine suppression test (prerequisite: systolic blood pressure > 120 mmHg): Following administration of clonidine, central inhibition of the sympathetic nervous system causes a decrease in plasma concentrations of catecholamine metabolites in healthy subjects, but not in cases of autonomic catecholamine secretion resulting from a pheochromocytoma.

Differential diagnosis
This section has been translated automatically.

Blood pressure crises of other genesis, especially in advanced renal insufficiency; in hyperglycaemia diabetes mellitus, hyperthyroidism, cocaine or amphetamine abuse; other tumours of the adrenal gland (e.g. ganglioneuromas).

Therapy
This section has been translated automatically.

Laparoscopic tumor removal (if not possible: open surgery).

For unilateral pheochromocytoma, perform unilateral adrenalectomy. For MEN-2 syndrome and bilateral tumors, perform bilateral subtotal (organ-preserving) adrenalectomy (lifelong glucocorticoid replacement therapy is avoided!).

At least one week before the procedure, blood pressure is lowered using an α-blocker (e.g., phenoxybenzamine); subsequently, a non-selective β-blocker is added. This therapeutic approach should be followed because surgical removal of the tumors releases large amounts of catecholamines (Naranjo J et al. 2017). Otherwise, conservative management: treatment of a hypertensive crisis.

If inoperable: Long-term therapy with α-blockers (phenoxybenzamine, prazosin).

For metastatic pheochromocytoma (detection of 123I-MIBG-positivemetastases): 131I-MIBG therapy(response rate approx. 25%); otherwise, the following treatment options are available: chemoembolization of liver metastases, palliative chemotherapy.

For unilateral pheochromocytoma: complete resection of the affected adrenal gland.

In the presence of MEN syndrome, only the adrenal medulla is removed bilaterally. In 80% of patients, catecholamine levels and blood pressure return to normal postoperatively.

If metastases develop, systemic radionuclide therapy, also known as endoradiotherapy, (MIBG therapy = metaiodobenzylguanidine, the radionuclide = 131I, a predominantly β-emitter) or polychemotherapy is performed.

Alternative: Phase II trial with the multityrosine kinase inhibitor sunitinib. 

Progression/forecast
This section has been translated automatically.

90% of adrenal pheochromocytomas are benign.

10% of adrenal pheochromocytomas are malignant.

In the case of extraadrenal tumors (see below: paragangliomas), approximately 30% are malignant.

 > 50% of patients with benign pheochromocytoma become normotensive after surgery; in the remaining cases, essential hypertension is also present. Over the long term, approximately 15% of patients experience a recurrence; therefore, follow-up examinations are indicated.

Note(s)
This section has been translated automatically.

A pheochromocytoma can also originate from the sympathetic border strand (parallel to the spinal column or major blood vessels) and is then called extra-adrenal pheochromocytoma or paraganglioma.

Literature
This section has been translated automatically.

  1. Cascon A et al (2009b) Genetics of pheochromocytoma and paraganglioma in Spanish patients. Journal of Clinical Endocrinology and Metabolism 94: 1701-1705.
  2. Farrugia FA et al (2019) Pheochromocytoma. Endocr Regul 53:191-212.
  3. DeLellis RA et al (2004) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organ. Lyon, France: IARC Press; S 147-166.
  4. Fishbein L (2016) Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment. Hematol Oncol Clin North Am 30:135-150.
  5. Karagiannis A et al (2007) Pheochromocytoma: an update on genetics and management. Endocrine-Related Cancer 14: 935-956.
  6. Manger WM et al (2002) Pheochromocytoma. J Clin Hypertens (Greenwich)4: 62-72.
  7. Mannelli M et al (2009) Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. Journal of Clinical Endocrinology and Metabolism 94: 1541-1547.
  8. Naranjo J et al (2017) Perioperative Management of Pheochromocytoma. J Cardiothorac Vasc Anesth 31:1427-1439.
  9. Neumann HPH et al (2019) Pheochromocytoma and Paraganglioma. N Engl J Med 381:552-565.
  10. Scholz T et al.: Current Treatment of Malignant Pheochromocytoma. In: The Journal of Clinical Endocrinology Metabolism 92: 1217-1225.

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 04.11.2026